For many technology startups, the hardest part is not invention. It is everything that comes after.
A breakthrough in a university lab, a working prototype, or even an early customer pilot may prove that a product can exist. It does not prove that a company can scale. To get there, founders need to pay customers, patient capital, production partners, regulatory support, credible governance, and eventually, if the business is strong enough, access to public markets.
That difficult stretch between research and commercial scale is where many promising startups stumble. Hong Kong is now positioning itself as one of Asia’s key bridges across that gap, using a mix of public capital, private investment, industry partnerships and links to the Greater Bay Area’s manufacturing base.
Also Read: How HKSTP’s quarter-century journey offers insights for Asia’s innovation ecosystems
The effort matters beyond Hong Kong. Across Southeast Asia, governments and investors are also asking how to turn research, engineering talent and early-stage startups into companies that can compete regionally or globally. The lesson from Hong Kong is that building an innovation hub is no longer just about funding more startups. It is about connecting the entire commercialisation chain.
The funding gap after product-market promise
The most vulnerable period for many deeptech companies often comes after science has been proven, but before business is mature enough for mainstream capital.
A biotech startup may need years of clinical development before revenue arrives. A robotics company may require costly manufacturing and field testing. A semiconductor company may need specialist equipment, design talent and supply-chain partners long before it can show predictable cash flow.
At this stage, conventional bank lending is often unavailable, while later-stage institutional investors may still consider the risks too high. If capital dries up, companies can lose momentum just when they need to spend more on product development, hiring, certification, production or market entry.
Hong Kong Science and Technology Parks Corporation, better known as HKSTP, is narrowing that financing gap. Demonstrating forward-thinking vision, its Venture Fund was established in 2015, and now manages HK$1 billion (~US$128 million) and covers 117 technology companies. According to figures supplied by HKSTP, every HK$1 invested through the fund has on average attracted about HK$13 in private-market investment.
HKSTP also has a separate HK$500 million (~US$64 million) public-private fund under its Co-Acceleration programme. This combines capital with industry resources, investment expertise and market access for deep-tech companies.
That leverage effect is important. Public funding alone rarely builds large companies. But when it helps reduce early risk, pull in private investors and connect startups with customers, it can become a catalyst rather than a subsidy.
From isolated winners to a repeatable pipeline
Hong Kong already has examples of companies moving from its innovation ecosystem to the public markets. HKSTP says 23 companies from its ecosystem had gone public by the beginning of this year, spanning artificial intelligence, life sciences, robotics and semiconductors.
One closely watched case is Insilico Medicine, the AI drug-discovery company that set up an R&D centre at Science Park in 2019 and listed in Hong Kong at the end of last year. Its first AI-designed drug candidate has advanced to Phase III clinical trials, while its IPO raised HK$2.277 billion, or about US$292 million, making it the city’s largest biotech IPO of the year.
Also Read: Why Hong Kong’s metro just became every marketer’s dream
But one listing, or even a handful of them, does not make an ecosystem.
The harder question is whether those outcomes can be repeated. That depends on whether young companies can consistently move from research to pilot projects, from pilots to commercial contracts, from small-scale production to volume manufacturing, and from private capital to public-market readiness.
This is particularly relevant for Southeast Asia, where many ecosystems have become more sophisticated over the past decade but still face commercialisation bottlenecks. The region has produced major consumer internet, fintech and logistics companies, yet deep-tech sectors such as robotics, biotech, advanced manufacturing and semiconductors need a different kind of support structure. They require patient capital, technical infrastructure, enterprise customers and links to industrial supply chains.
Hong Kong’s pitch is that it can bring some of these pieces together.
Why the Greater Bay Area matters
Hong Kong’s strength is not only its capital market. It also has research universities, professional services, intellectual-property protection and access to international investors. But its broader commercialisation advantage lies in its connection to the Greater Bay Area.
The GBA links Hong Kong with cities including Shenzhen, Guangzhou, Dongguan and others in southern China. For hardware, robotics, biotech tools and semiconductor-related startups, that proximity can be significant. Companies can tap engineering expertise, suppliers, prototyping facilities and manufacturing capacity across the region while using Hong Kong for finance, legal structuring and global market access.
In practice, this means a startup may conduct R&D in Hong Kong, source components from Dongguan, work with manufacturing partners in Shenzhen, raise capital from international investors, and eventually sell into Asia, Europe or North America.
That model reflects how modern commercialisation actually works. Innovation no longer sits neatly inside one city. Research, funding, product development, production and customers are often spread across multiple markets.
For Southeast Asian founders, the parallel is clear. A Singapore-based medtech company may test products in Vietnam, manufacture in Malaysia, raise capital from regional funds and sell to hospitals across Indonesia or Thailand. The challenge is not simply to invent, but to coordinate a regional pathway from invention to adoption.
Taking technology to customers
This is the context for HKSTP’s Co-Development & Investment Conference, or CDIC, a six-day programme spanning Hong Kong, Dongguan and Hangzhou.
The programme brings together founders, investors and industry representatives in what HKSTP describes as a “Tri-Party Ecosystem”. The aim is to combine capital with commercial matching, giving technology companies access to possible applications and financing while helping investors identify companies with growth potential.
The inclusion of industry use cases is crucial. Startups do not scale because investors like a pitch deck. They scale because customers find a product useful enough to buy, integrate and keep using.
That distinction matters more as technology becomes easier to build. AI tools, cloud infrastructure and open-source software have lowered the barrier to developing new products. But they have not lowered the difficulty of selling into regulated industries, integrating with enterprise systems or proving return on investment to customers.
Technical validation answers the question: does it work? Commercial validation asks a tougher one: will anyone pay for it at scale?
Each CDIC location appears to serve a different role. Hong Kong contributes capital, financial infrastructure and international connectivity. Dongguan offers access to manufacturing and supply chains. Hangzhou adds another major technology and R&D cluster.
Also Read: Hong Kong’s pitch to SEA: “We want to be your super partner”
Together, they point to a more pragmatic model of ecosystem building: bring startups closer not only to investors, but also to factories, customers and sector experts.
IPO as a test, not the destination
Hong Kong’s public markets are another part of this pathway. The city’s listing regimes under Chapters 18A and 18C have created routes for biotech and specialist technology companies that may not yet meet conventional profit or revenue requirements.
That matters because deep-tech companies often require long development cycles before they resemble traditional listed businesses. Biotech firms, for instance, may need years of clinical trials. Advanced hardware companies may have high upfront capital expenditure before revenue scales.
A public listing can give such companies access to growth capital and allow early investors to return money to their own backers. Those returns can then be recycled into the next generation of startups.
Still, an IPO should not be mistaken for the end goal. The real test is whether companies can build durable businesses after listing, withstand public-market scrutiny and keep investing in innovation.
For Hong Kong, the commercialisation push is therefore about more than producing the next unicorn or IPO candidate. It is about proving that research, capital, manufacturing and market access can be joined into a repeatable system.
For Southeast Asia, watching that experiment will be useful. The region has no shortage of entrepreneurial energy. Its next challenge is building stronger bridges between invention and industry.
The final mile remains the hardest part of the journey. Hong Kong is betting that ecosystems which can make that stretch less punishing will have the edge in the next phase of Asia’s tech economy, and HKSTP is leading the charge locally to make that happen.s
The post How Hong Kong solves tech’s hardest problem: the final mile to market appeared first on e27.